Literature DB >> 15020078

CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.

Koichi Narikawa1, Tatsuro Misu, Kazuo Fujihara, Ichiro Nakashima, Shigeru Sato, Yasuto Itoyama.   

Abstract

The pathogenesis of relapsing neuromyelitis optica (RNMO) remains unknown. We, for the first time, studied the levels of four chemokines in the cerebrospinal fluid in RNMO with ELISA and compared the data with those in multiple sclerosis (MS) and control. CXCL10/IP-10 and CCL17/TARC were significantly elevated in both RNMO and MS. Conversely, CCL2/MCP-1 was significantly lower in MS, but not in RNMO, than in control. CCL11/Eotaxin was not different between groups. None of the four chemokines studied was significantly different between RNMO and MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020078     DOI: 10.1016/j.jneuroim.2003.12.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica.

Authors:  Koichi Narikawa; Tatsuro Misu; Kazuo Fujihara; Ichiro Nakashima; Shigeru Sato; Yasuto Itoyama
Journal:  J Neurol       Date:  2005-07-18       Impact factor: 4.849

3.  An Experimental Animal Model of Photodynamic Optic Nerve Head Injury (PONHI).

Authors:  Dimosthenis Mantopoulos; Peggy Bouzika; Athanassios Tsakris; Basil S Pawlyk; Michael A Sandberg; Joan W Miller; Joseph F Rizzo Iii; Demetrios G Vavvas; Dean M Cestari
Journal:  Curr Eye Res       Date:  2016-05-09       Impact factor: 2.424

4.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

5.  TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.

Authors:  Andrew D Cook; Ming-Chin Lee; Reem Saleh; Hsu-Wei Khiew; Anne D Christensen; Adrian Achuthan; Andrew J Fleetwood; Derek C Lacey; Julia E Smith; Irmgard Förster; John A Hamilton
Journal:  JCI Insight       Date:  2018-03-22

6.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

7.  Theiler's virus infection provokes the overexpression of genes coding for the chemokine Ip10 (CXCL10) in SJL/J murine astrocytes, which can be inhibited by modulators of estrogen receptors.

Authors:  Nazario Rubio; Maria-Angeles Arevalo; Marie Cerciat; Francisco Sanz-Rodriguez; Mikko Unkila; Luis Miguel Garcia-Segura
Journal:  J Neurovirol       Date:  2014-07-23       Impact factor: 2.643

Review 8.  [Neuromyelitis optica].

Authors:  S Jarius; B Wildemann
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

9.  Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Chriso Tsikkou; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

10.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.